Melanoma and Immunotherapy

Alexander M.M. Eggermont; Dirk Schadendorf

doi:10.1016/j.hoc.2009.03.009

Melanoma and Immunotherapy

Alexander M.M. Eggermont, Dirk Schadendorf

Research output: Contribution to journal › Review article › peer-review

41 Citations (Scopus)

Abstract

About 20% of all primary melanomas will spread. The likelihood of metastatic behavior correlates with prognostic factors such as tumor thickness, mitotic index, presence of ulceration, lymphocyte infiltration, age, gender, and anatomic site. Immunotherapies are developed for melanoma patients in stage IV who have distant metastases and in stage II to III patients in the adjuvant micrometastatic setting, where only a fraction of patients have widespread (microscopic) disease.

Original language	English
Pages (from-to)	547-564
Number of pages	18
Journal	Hematology/Oncology Clinics of North America
Volume	23
Issue number	3
DOIs	https://doi.org/10.1016/j.hoc.2009.03.009
Publication status	Published - Jun 2009
Externally published	Yes

Keywords

Antibodies
Cytokines
Immunotherapy
Melanoma
Review
Vaccines

Access to Document

10.1016/j.hoc.2009.03.009

Cite this

@article{2668bccc29ed421da9152bd399a2c058,

title = "Melanoma and Immunotherapy",

abstract = "About 20% of all primary melanomas will spread. The likelihood of metastatic behavior correlates with prognostic factors such as tumor thickness, mitotic index, presence of ulceration, lymphocyte infiltration, age, gender, and anatomic site. Immunotherapies are developed for melanoma patients in stage IV who have distant metastases and in stage II to III patients in the adjuvant micrometastatic setting, where only a fraction of patients have widespread (microscopic) disease.",

keywords = "Antibodies, Cytokines, Immunotherapy, Melanoma, Review, Vaccines",

author = "Eggermont, {Alexander M.M.} and Dirk Schadendorf",

year = "2009",

month = jun,

doi = "10.1016/j.hoc.2009.03.009",

language = "English",

volume = "23",

pages = "547--564",

journal = "Hematology/Oncology Clinics of North America",

issn = "0889-8588",

publisher = "W.B. Saunders",

number = "3",

}

TY - JOUR

T1 - Melanoma and Immunotherapy

AU - Eggermont, Alexander M.M.

AU - Schadendorf, Dirk

PY - 2009/6

Y1 - 2009/6

N2 - About 20% of all primary melanomas will spread. The likelihood of metastatic behavior correlates with prognostic factors such as tumor thickness, mitotic index, presence of ulceration, lymphocyte infiltration, age, gender, and anatomic site. Immunotherapies are developed for melanoma patients in stage IV who have distant metastases and in stage II to III patients in the adjuvant micrometastatic setting, where only a fraction of patients have widespread (microscopic) disease.

AB - About 20% of all primary melanomas will spread. The likelihood of metastatic behavior correlates with prognostic factors such as tumor thickness, mitotic index, presence of ulceration, lymphocyte infiltration, age, gender, and anatomic site. Immunotherapies are developed for melanoma patients in stage IV who have distant metastases and in stage II to III patients in the adjuvant micrometastatic setting, where only a fraction of patients have widespread (microscopic) disease.

KW - Antibodies

KW - Cytokines

KW - Immunotherapy

KW - Melanoma

KW - Review

KW - Vaccines

UR - http://www.scopus.com/inward/record.url?scp=65649126818&partnerID=8YFLogxK

U2 - 10.1016/j.hoc.2009.03.009

DO - 10.1016/j.hoc.2009.03.009

M3 - Review article

C2 - 19464602

AN - SCOPUS:65649126818

SN - 0889-8588

VL - 23

SP - 547

EP - 564

JO - Hematology/Oncology Clinics of North America

JF - Hematology/Oncology Clinics of North America

IS - 3

ER -

Melanoma and Immunotherapy

Abstract

Keywords

Access to Document

Fingerprint

Cite this